Pharmacogenomics Shapes Safer NHS Prescribing in 2026
The NHS has entered a decisive phase in the use of pharmacogenomics, moving from targeted pilots to routine medicines optimisation informed by genetic data. By 2026, evidence from national implementation programmes shows that pharmacogenomic testing can materially reduce adverse drug reactions and improve therapeutic response when embedded directly into clinical workflows. The promise of delivering […]